Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Nov 2012
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease.
In Crohn's disease (CD), knockdown of Smad7, an inhibitor of Transforming Growth Factor (TGF)-β1 activity, with a specific antisense oligonucleotide (GED0301) seems to be safe and tolerable and associates with TGF-β1-mediated suppression of inflammatory pathways. ⋯ Short-term treatment of patients with Crohn's disease using GED0301 is not associated with the development of small bowel stricture, thus reinforcing the concept that this drug is safe at least at early time points.
-
Aliment. Pharmacol. Ther. · Nov 2012
Acute diverticulitis: demographic, clinical and laboratory features associated with computed tomography findings in 741 patients.
Computed tomography (CT) demonstrates diverticulitis severity. ⋯ Less than 50% of severe cases have the clinical/laboratory triad of abdominal pain, fever and leucocytosis, but only 1 of 20 with pain who lack fever and leucocytosis have severe diverticulitis. Male gender, pain not limited to the lower abdomen, constipation, fever and leucocytosis are independently associated with severe diverticulitis.
-
Aliment. Pharmacol. Ther. · Nov 2012
Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis.
There is increasing evidence that proton pump inhibitors (PPIs) increase the rate of infections in patients with decompensated cirrhosis. ⋯ Among patients with decompensated cirrhosis, proton pump inhibitors but not H2 receptor antagonists increase the rate of serious infections.